OVERVIEW

Neurology: Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis is organized by American Academy of Neurology (AAN).

Released: 2/27/2018
Expires: 2/27/2021

Target Audience:
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.

Accreditation:
AMA Credit Designation Statement
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Conference Objectives are :
Upon completion of the article by Charidimou et al, the participant should be able to:
• Discuss differences in β-amyloid (Aβ) levels in the cerebrospinal fluid (CSF) of patients with cerebral amyloid angiopathy (CAA) and healthy controls in this study
• Describe differences in Aβ levels in the CSF of patients with CAA compared to patients with Alzheimer disease (AD) in this study
• Identify which subgroups of patients in this study were found to have higher CSF levels of total and phosphorylated tau

Additional details will be posted as soon as they are available.